Organization | Heat Biologics

Heat Biologics Report issue

For profit Phase 1 Phase 2 Phase 4

Founded: Chapel Hill NC United States (2008)

Organization Overview

First Clinical Trial

2011

NCT01504542

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Heat Biologics

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: Heat Biologics (0) Acquired (1)

obiltoxaximab (anthim) (7 trials)

Drugs in Phase 2 Trials (11)

bacille calmette-guerin (1 trial)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (1 trial)

erlotinib (tarceva) (1 trial)

gemcitabine (gemzar) (1 trial)

hs-410 (1 trial)

nivolumab (opdivo) (1 trial)

paclitaxel (taxol) (1 trial)

pemetrexed (alimta) (1 trial)

viagenpumatucel-l (4 trials)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (3)

Key: Heat Biologics (2) Acquired (1)

ciprofloxacin (cipro) (1 trial)

hs-130 (1 trial)

ptx-35 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 14
# of Trial APIs: 15